You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

NAPROXEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Naproxen patents expire, and what generic alternatives are available?

Naproxen is a drug marketed by Amneal, Hetero Labs Ltd Iii, Hikma, Novitium Pharma, Actavis Elizabeth, Aurobindo Pharma Usa, Fosun Pharma, Nuvo Pharms Inc, Pliva, Teva, Tulex Pharms Inc, Amneal Pharms Ny, Aurobindo Pharma, Chartwell Molecules, Dava Pharms Inc, Glenmark Pharms Ltd, Granules, Hamilton Pharms, Hikma Intl Pharms, Invagen Pharms, Ivax Sub Teva Pharms, L Perrigo Co, Marksans Pharma, Norvium Bioscience, Purepac Pharm, Roxane, Sciegen Pharms Inc, Teva Pharms, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Dr Reddys, Mylan, Bionpharma, Catalent, Patheon Softgels, Puracap Pharm Llc, Strides Pharma, Able, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Granules India, Hetero Labs Ltd V, Lnk Intl Inc, Novelgenix Theraps, Perrigo, Pld Acquisitions Llc, Sandoz, Sun Pharm Inds Ltd, Yichang Humanwell, Amneal Pharms Co, Corepharma, P And L, and Perrigo R And D. and is included in eighty-nine NDAs. There are five patents protecting this drug.

The generic ingredient in NAPROXEN is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NAPROXEN?
  • What are the global sales for NAPROXEN?
  • What is Average Wholesale Price for NAPROXEN?
Drug patent expirations by year for NAPROXEN
Drug Prices for NAPROXEN

See drug prices for NAPROXEN

Drug Sales Revenue Trends for NAPROXEN

See drug sales revenues for NAPROXEN

US Patents and Regulatory Information for NAPROXEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva NAPROXEN naproxen TABLET;ORAL 074129-001 Dec 21, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sciegen Pharms Inc NAPROXEN AND ESOMEPRAZOLE MAGNESIUM esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 217738-001 Oct 11, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hamilton Pharms NAPROXEN naproxen TABLET;ORAL 074110-003 Oct 30, 1992 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dava Pharms Inc NAPROXEN naproxen TABLET;ORAL 074105-003 Dec 21, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074455-001 May 31, 1995 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sciegen Pharms Inc NAPROXEN SODIUM naproxen sodium TABLET;ORAL 212199-001 Oct 30, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.